Stalicla secures CHF 2M investment led by Addex for neuropsychiatric drug development
Source: SeekingAlpha
2025-06-30 03:32:02 ET
Addex Therapeutics ( NASDAQ: ADXN ) has led a CHF 2 million investment in Stalicla, a company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders....
Read the full article on Seeking Alpha
For further details see:
Stalicla secures CHF 2M investment led by Addex for neuropsychiatric drug development
Addex Therapeutics Ltd
NASDAQ: ADXN
ADXN Trading
-0.03% G/L:
$7.2581 Last:
1,218 Volume:
$7.26 Open:
ADXN Latest News
September 12, 2025 01:30:22 pm
PRISM Midday Movers: Addex Therapeutics and Esports Entertainment Surge on High Volume and Renewed Speculation
ADXN Stock Data
$12,125,314
1,320,996
N/A
13
N/A
Biotechnology & Life Sciences
Healthcare
CH
Geneva
